"Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic. I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world as the largest broad-based healthcare company, enabled us to lead in the fight against COVID-19. We continue to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon. Johnson & Johnson was built for times like these, and I am extremely confident in our ability to deliver lasting value and continued innovation in 2021 and for years to come."

**Worldwide Consumer Health Sales**
Consumer Health worldwide reported sales increased 1.1% or 3.0% operationally.1 Primary operational drivers:

- Tylenol
- Listerine
- Aveeno
- Band-Aid
- Zantac
- OTC

**Worldwide Pharmaceutical Sales**
Pharmaceutical worldwide reported sales increased 8.0% or 8.2% operationally.1 Primary operational drivers:

- Stelara
- Imbruvica
- Tremfya
- Janssen
- Eltvvec

**Worldwide Medical Devices Sales**
Medical Devices worldwide reported sales decreased (11.6%) or (11.4%) operationally.1 Offsets to decline:

- Electrophysiology
- Neurovascular

Note: values may have been rounded.


1. The Q3-2020 financial measures noted are Q3-2020 financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

2. The Q4-2020 financial measures exclude the impact inherent to quarterly currency.

3. The Q4-2020 earnings per share reflect the impact of a non-recurring item described in the ‘Other (gain) loss’ section of the income statement.

4. The Q3-2020 earnings per share reflect the impact of a non-recurring item described in the ‘Other (gain) loss’ section of the income statement.

5. The Q3-2020 earnings per share reflect the impact of a non-recurring item described in the ‘Other (gain) loss’ section of the income statement.

6. The Q4-2020 earnings per share reflect the impact of a non-recurring item described in the ‘Other (gain) loss’ section of the income statement.

7. The Q4-2020 earnings per share reflect the impact of a non-recurring item described in the ‘Other (gain) loss’ section of the income statement.

8. The Q4-2020 earnings per share reflect the impact of a non-recurring item described in the ‘Other (gain) loss’ section of the income statement.